✦ LIBER ✦

Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV)

✍ Scribed by Schwartzberg, Lee; Barbour, Sally Y.; Morrow, Gary R.; Ballinari, Gianluca; Thorn, Michael D.; Cox, David

Book ID: 121579303
Publisher: Springer-Verlag
Year: 2013
Tongue: English
Weight: 316 KB
Volume: 22
Category: Article
ISSN: 0941-4355
DOI: 10.1007/s00520-013-1999-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Ondansetron versus granisetron in the pr

Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting

✍ Paola Fedele; Michele Spina; Mariagrazia Valentini; Doriana Collini; Cadorin Luc 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 229 KB 👁 2 views

A phase III open-label study to assess s

A phase III open-label study to assess safety and efficacy of palonosetron for preventing chemotherapy-induced nausea and vomiting (CINV) in repeated cycles of emetogenic chemotherapy

✍ Kenjiro Aogi, Hiroshi Sakai, Hirohisa Yoshizawa, Norikazu Masuda, Nobuyuki Katak 📂 Article 📅 2011 🏛 Springer-Verlag 🌐 English ⚖ 227 KB

Granisetron is just as effective as onda

Granisetron is just as effective as ondansetron in the complete prevention of chemotherapy-induced nausea and vomiting

✍ Karen B. Domino 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 186 KB

Palonosetron plus dexamethasone versus g

Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial

✍ Mitsue Saito; Kenjiro Aogi; Ikuo Sekine; Hirohisa Yoshizawa; Yasuhiro Yanagita; 📂 Article 📅 2009 🏛 The Lancet 🌐 English ⚖ 140 KB

Randomized, double-blind, crossover stud

Randomized, double-blind, crossover study of palonosetron compared with granisetron for the prevention of chemotherapy-induced nausea and vomiting in a Chinese population

✍ Weihua Tian; Zhiqiang Wang; Juntian Zhou; Shucai Zhang; Jinghui Wang; Qiang Chen 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 246 KB

Improved prevention of moderately emetog

Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist : Results of a Phase III, single-dose trial versus dolasetron

✍ Peter Eisenberg; Jazmin Figueroa-Vadillo; Rosalio Zamora; Veena Charu; Julio Haj 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 174 KB

## Background: Palonosetron, a highly selective and potent 5-ht(3) receptor antagonist with a strong binding affinity and a long plasma elimination half-life (approximately 40 hours), has shown efficacy in phase ii trials in preventing chemotherapy-induced nausea and vomiting (cinv) resulting from